key: cord-0762854-5fpvsd0k
authors: Klassen, David
title: New Answers to Old questions: Wait List versus Transplant Outcomes in the COVID-19 Era
date: 2020-11-24
journal: Kidney Int Rep
DOI: 10.1016/j.ekir.2020.11.015
sha: 973ec8f9605669a438f5f8e488dd6d15a96df45e
doc_id: 762854
cord_uid: 5fpvsd0k

nan

The Covid-19 pandemic has dramatically affected health care systems and health outcomes around the world. Transplantation has responded with critical changes to the delivery of transplant services for patients awaiting organ transplants as well as for the larger group of previously transplanted recipients (1) (2) (3) . The complex clinical nature of these patients as well as the complicated infrastructure required to successfully deliver care to these patients has made the vulnerability of transplant systems apparent to all of us who work in this field.

The pandemic has also challenged assumptions about how we care for patients with end stage organ failure, including revisiting answers to basic questions long thought to have been resolved. Over 20 years ago, Wolfe and colleagues (4) published an analysis of survival data collected from patients on kidney transplant waiting lists and patients receiving kidney transplants in the United States Organ Procurement and Transplant Network (OPTNP). They showed that when adjusted for age, sex, race, cause of renal disease, and geographic region, survival was superior for patients receiving kidney transplants compared to patients who remained on waiting lists. This study and similar studies that followed established kidney transplantation as the treatment of choice for patients with end stage kidney disease.

In this issue of Kidney International Reports, Clarke and colleagues (5) from the Imperial College London's Hammersmith Hospital report in their paper "Informing the risk of kidney transplantation versus remaining on the wait list in the COVID-19 era" that in the environment of the COVID-19 global pandemic, these long held assumptions on the survival benefit of kidney transplantation and our clinical practices must be re-examined.

In their study of 299 wait list patients and 237 kidney transplant recipients within the first-year posttransplant, they found that the overall mortality rate of these groups was actually similar during the COVID-19 pandemic. COVID 19 was more likely to be diagnosed in the wait list patients who received more testing. The impact on overall mortality of diagnosed SARS-COV-2 infections in waitlist patients was, however, comparable to the impact on transplant recipients who had fewer documented infections but a substantially higher mortality rate (11.3 % vs 37.5% respectively). After adjusting for screening bias they reported that the risk of death was actually higher in transplant recipients {HR: 3.36 (1.19-9.50)}.

Issues that potentially confound the Clarke et al analysis include the retrospective nature and relatively small sample size as well as limitations of accurate identification of true cases. Their data on mortality in kidney transplant recipients are however, similar to those reported by others and with respect to medical risk factors associated with mortality, and the higher proportion of patients from Black and other ethnic minorities (6, 7) . An important question not addressed in their analysis is how a diagnosis of COVID-19 in waitlisted patients who recover will affect their transplant candidacy and outcomes going forward. The impact of lost opportunity for future transplantation is difficult to assess and should be factored into decisions on whether to remain on a waiting list or proceed with transplantation.

A model of transplant mortality recently developed by Massie and colleagues (8) suggests that the risk benefit ratio of transplantation versus remaining on the waitlist depends primarily on the case fatality rate for transplant recipients who acquire Covid-19. Data on this issue continue to evolve but are often reported in the range observed by Clarke with particularly high mortality rates among transplant recipients contracting COVID-19 early following transplantation. It should be recognized that these data have the potential to vary on a "micro" level and may be hospital specific. This argues for the value of continual assessment of local data and resources by transplant providers to guide decision making in addition to using system-wide or national high-level guidelines. As clinical experience accumulates, reports which include data from broader populations transplant recipients suggest rates of mortality may be lower than initially reported. Mortality rates can be expected to further change as effective therapies for COVID-19 emerge and if vaccines with long-term efficacy in transplant populations are developed.

Despite uncertainty about precise mortality rates, Clarke's paper nonetheless poses important questions that must be confronted by transplant patients and providers. The decision as to whether to proceed with kidney transplantation or recommend patients to delay transplantation until the pandemic wanes remains difficult. The data are constantly changing and require continual assessment by providers and patients. The outcomes for transplant recipients and wait list patients who face these complex decisions will evolve as the pandemic continues to unfold and will be influenced by the responses of healthcare systems and policy makers to the many challenges posed by the pandemic.

Organ donation during the COVID-19 pandemic

Early national and center-level changes to kidney transplantation in the United States during the COVID-19 epidemic

Covid-19-related collapse of transplantation systems: a heterogenous recovery?

Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant

Informing the risk of kidney transplantation versus remaining on the waiting list in the COVID-19 era

Clinical characteristics and outcomes of COVID-19 in solid organ transplant recipients: a cohort study

SARS-CoV-2 infection and early mortality of waitlistd and solid organ transplant recipients in England: a national cohort study

Identifying scenarios of benefit or harm from kidney transplantation during the COVID-19 pandemic: a stochastic simulation and machine learning study